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1. ABSTRACT
The effects of felodipine (2.5-5.0 mg po BID) versus placebo were
evaluated in fourteen patients with concomitant coronary artery disease
and congestive heart failure already receiving stable doses of enalapril,
furosemide,

and

digoxin

randomized

trial.

in

a

Felodipine,

ten-week,
a

prospective,

dihydropyridine

double-blind,

calcium

channel

antagonist, has been found to possess potent peripheral and coronary
vasodilatory action without a significant negative inotropic effect in
numerous

in

vivo and in

vitro studies.

However, long

term

use of

felodipine as add-on therapy to CHF patients already receiving maximal
medical therapy has not yet been examined.
Baseline thallium-201 scintigraphy performed on all subjects prior to
randomization

revealed

electrocardiographically

a

silent

58%

incidence

myocardial

of

ischemia.

clinically

and

Furthermore, the

addition of felodipine was found to reduce the normalized area of ischemic
myocardium (-29.0% +/- 9.5, p<.05) in subjects with initial thallium scans
revealing

greater

than

10%

reversible

perfusion

defects.

Persistent

afterload reduction was also noted following eight weeks of felodipine
therapy versus placebo with decreases in mean systolic blood pressure
(-19.7 mm Hg +/- 8.3, p<.01) and diastolic blood pressure (-5.4 mm Hg +/6.5, p<.05). Given the statistical constraints imposed by the relatively
small sample size, no associated benefit in terms of either exercise
tolerance, functional status, or quality of life assessment was found.
Future studies documenting the clinical efficacy of felodipine in
coronary patients limited by symptoms of CHF and having scintigraphic
evidence of 10% or greater reversible myocardial ischemia are warranted.
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2. INTRODUCTION

The prevalence of chronic congestive heart failure (CHF) is increasing with more
than two million people in the United States alone afflicted by this syndrome which
carries an associated high rate of mortality and morbidity (1). In the United States,
coronary artery disease is the most common etiology, apparently due to an overall
decline in the death rate from ischemic heart disease and a subsequent increase in the
number of coronary patients surviving with poor left ventricular function. Patients
experiencing symptoms of CHF are commonly encountered both inside the private
offices of internists and cardiologists as well as occupying an ever greater portion of
hospital inpatient beds nationwide.
Although clearly effective as antihypertensive and antianginal agents, the role of
calcium channel antagonists in the treatment of symptomatic congestive heart failure
has yet to be determined. Because the majority of patients with CHF have it on the
basis of ischemic heart disease, anti-ischemic therapy is rational and, yet, has not been
found to be of significant benefit as presently utilized. Delineation of a treatment
program designed to maximize hemodynamics while minimizing ischemia could be
beneficial to a large segment of the CHF population. Felodipine, a calcium channel
antagonist with an apparent lack of negative inotropic effect, would appear to be an
ideal drug for this purpose.
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3. EPIDEMIOLOGY OF CONGESTIVE HEART FAILURE

Despite the recent decline in overall cardiovascular mortality, the prevalence of
CHF nationwide has continued to increase with the majority of new cases of ventricular
dysfunction being due to coronary artery disease (2). It is estimated that about 3 million
Americans have CHF, representing approximately 1% of the population (3). Given
recent growth in the geriatric population and the increased incidence of CHF with age,
the magnitude of this problem can be expected to increase over the next several
decades. Currently, about 400,000 new cases of CHF are diagnosed every year in the
United States with the number of hospitalizations partly or wholly due to this condition
nearly doubling over the last ten years (4). CHF is now the most common hospital
discharge diagnosis for those over the age of 65.
The current prognosis with CHF is poor as approximately 200,000 patients die
from complications each year. The status of left ventricular function has been found to
be the single best predictor of mortality in most subgroups of patients with coronary
artery disease. Those patients in whom ventricular dysfunction coexists with
asymptomatic or "silent" ischemia constitute the highest risk group (5). Data from the
Framingham study demonstrated a two year mortality rate of 31% and a four year
mortality rate of 52% among patients with congestive failure (6). Individuals with New
York Heart Association class IV symptoms have nearly a 50% risk of death within only
one year (4). Despite improvements in survival with the addition of vasodilators to the
treatment of CHF, prognosis remains formidible with currently reported one-year and
three-year mortality rates equaling 25% and 65%, respectively (7). To cast these
mortality rates in perspective, survival at one and three years following a diagnosis of
metastatic squamous cell carcinoma of the lung nearly approximates that of patients
with CHF (8).
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4. PATHOPHYSIOLOGY OF ISCHEMIC CARDIOMYOPATHY AND
CONGESTIVE HEART FAILURE

Insight into the pathophysiology of ischemic cardiomyopathy and congestive
heart failure provides the rationale for designing an effective and safe medical regimen
for use in this patient population.

A. Ischemic Cardiomyopathy
The pathogenesis of left ventricular dysfunction in patients with coronary artery
disease is thought by many to be multifactorial. In addition to irreversible areas of
infarction

and myocardial necrosis,

reversible or active

ischemia, "stunned

myocardium," and "hibernating myocardium" may contribute variably to the overall
systolic and diastolic dysfunction observed. Stunned myocardium refers to a reversible
condition in which an ischemic segment of myocardium displays persistent impairment
of contractility and diastolic relaxation for up to several days following restoration of
normal blood flow. Hibernating myocardium is another reversible condition in which
"myocardial perfusion is chronically reduced, but is still sufficient to maintain the
viability of the tissue...Myocardial function may remain impaired permanently or for as
long as myocardial perfusion is inadequate" (12).
In turn, the clinical spectrum of what has been termed "ischemic cardiomyopathy"
is also varied. Patients may merely exhibit asymptomatic left ventricular dysfunction
although symptomatic angina pectoris is frequently noted. Those patients who exhibit
asymptomatic, or "silent," ischemia may do so spontaneously or exclusively following
periods of stress and/or activity. It remains unknown to what extent such patients with
evidence for silent myocardial ischemia exhibit left ventricular dysfunction though
others have speculated that perhaps "repeated episodes of silent ischemia, though
brief, or silent infarction, though small, may result in congestive ischemic
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cardiomyopathy.” (13). Indeed, in one small series of patients with severe painless
ischemia, there is evidence for such a progression from silent myocardial ischemia to
marked left ventricular dysfunction and pulmonary edema (14). Survival among
patients with this syndrome, as in other types of cardiomyopathies, is directly related to
the degree of left ventricular dysfunction (15), while constituting the subgroup of CHF
patients at greatest risk for terminal events (5).

B. Congestive Heart Failure
Congestive heart failure (left-sided) can be broadly defined as a clinical
syndrome in which the heart is unable to pump sufficient amounts of blood from the
pulmonary vasculature to the systemic circulation so as to meet the metabolic needs of
peripheral tissues, resulting in a symptom complex composed of dyspnea, generalized
fatigue, and a reduction in exercise tolerance. However, absolute reduction in cardiac
output as a sole criterion for the definition of CHF has limitations. Rather, the cardiac
output, metabolic requirements, and left ventricular filling pressures all play essential
roles in the clinical presentation of CHF.
The potential causes of congestive heart failure are extremely varied (Table 1). In
essence, any process that leads to inadequate cardiac output, greater metabolic
demand, and/or increasing filling pressures may culminate in the clinical symptom
complex of CHF. In current series in the United States, it appears that in about 50 to
75% of patients with heart failure, coronary artery disease is the underlying cause (7).
Other etiologies include increased work load due to hypertension or valvular heart
disease, abnormal anatomy, altered cardiac rhythm or conduction, and "high output
states" such as those associated with fever, sepsis, hyperthyroidism, and cocaine and
amphetamine abuse. Diastolic dysfunction is also being recognized increasingly as a
cause of CHF with the left ventricle failing to relax sufficiently to permit diastolic filling at
normal pressures.
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TABLE 1: Causes of Congestive Heart Failure
Mechanical Abnormalities
a. Increased pressure load
i. Central (aortic stenosis, etc.)
ii. Peripheral (systemic hypertension, etc.)
b. Increased volume load (valvular regurgitation, etc.)
c. Obstruction to ventricular filling (mitral or tricuspid stenosis)
d. Pericardial constriction, tamponade
e. Endocardial or myocardial restriction
f. Ventricular aneurysm
g. Ventricular dyssynergy

Altered Cardiac Rhythm or Conduction Sequence
a.
b.
c.
d.

Standstill
Fibrillation
Extreme tachycardia or bradycardia
Electrical asynchrony, conduction disturbances

Myocardial Abnormalities
a. Primary
i. Cardiomyopathy
ii. Neuromuscular disorders
iii. Myocarditis
iv. Metabolic (diabetes, etc.)
v. Toxic (alcohol, cobalt, etc.)
vi. Presbycardia
b. Secondary
i. Ischemia
ii. Dysdynamic disorders
iii. Metabolic disorders
iv. Inflammation
v. Infiltrative diseases
vi. Systemic disease
vii. COPD
viii. Depression (due to drugs)

Adapted from Hurst JW, et al. The Heart, 6th edition. New York: McGraw-Hill Book Company (1986), p. 320.

Progressive weakening of the left ventricle with an attendant decrease in cardiac
output is manifested by rises in left ventricular end-diastolic pressure, left atrial
pressure, pulmonary venous pressure, and, finally, pressures within the pulmonary
capillary bed. The elevated pulmonary pressures, in turn, lead to interstitial edema and
alveolar edema with accumulations of fluid in the air spaces of the lungs, subjective
difficulty in breathing, and, ultimately, hypoxia and hypercapnia. The pathophysiology
of CHF can best be understood by dividing the determinants of cardiac function into
three aspects: preload, contractility, and afterload. It is the interaction between the left
ventricle and its loading conditions (preload and afterload) which determines the full
expression of the congestive heart failure state.
Physiologically, preload refers to the degree of myocardial fiber stretch at the
conclusion of diastole. Clinically, preload refers to the volume of blood residing within
the ventricles just prior to the advent of systole and ejection. The Frank-Starling law
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relating ventricular function to preload states that as the end-diastolic fiber stretch or
volume increases, greater stroke volume and, hence, cardiac output will result (Figure
1). However, since it is difficult to measure either individual cardiac muscle fiber length
or dynamic changes in ventricular volume, left ventricular end-diastolic pressure is
used as an indirect measurement of preload, assuming constant compliance. During
heart failure the Frank-Starling relationship is altered such that greater left ventricular
filling pressures become required to compensate for the primary myocardial insult and
produce the original stroke volume (Figure 1). Such compensatory states may
subsequently develop into "vicious cycles" in which continued increases in left
ventricular volumes and pressures ultimately lead to further ventricular dysfunction and
worsening pulmonary and systemic venous congestion.

FIGURE 1: Frank-Starling Relationship in Normal Heart vs. Failing Heart

Left ventricular end-diastolic volume
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A fundamental problem for patients with systolic dysfunction is a decline in
myocardial contractility. Contractility refers to the mechanical performance of the heart
and the ability of cardiac myofilaments to overlap and shorten against a load. In
patients with ischemic heart disease, loss of muscle due to myocardial infarction
imposes an additional volume and wall stress load on the remaining normal
myocardium. These changes lead to remodeling of the ventricle over time, with fibrosis
in regions of infarct and hypertrophy of the surrounding intact myocardium. Eventually,
the hypertrophied tissue may exhibit an intrinsic decrease in contractility and contract
abnormally, leading to further decline in overall cardiac function (16). An overall
reduction in myocardial contractility is manifested by a decrease in force and velocity of
shortening at given loading conditions. These preload and afterload-dependent indices
of contractility are reflected in a decline in left ventricular ejection fraction and stroke
volume and an attendant increase in left atrial pressure.
Afterload represents the sum resistance which the ventricle must overcome in
order to expel blood from the filled heart, including the amount of left ventricular wall
stress that must be developed, resistance across the aortic valve, and elasticity of the
aorta and immediate branching great vessels. Unlike the normal left ventricle, which is
relatively sensitive to changes in preload and insensitive to changes in afterload, the
failing

left

ventricle

has

the

opposite

characteristics

and

is

exquisitely

afterload-sensitive (Figure 2). Assuming there is no aortic stenosis, a reasonable,
indirect measure of afterload is systemic vascular resistance. Consequently, relatively
small increases in systemic vascular resistance may significantly reduce stroke volume
in CHF patients in whom a fragile compensatory balance exists between left ventricular
preload, afterload and contractility.
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FIGURE 2: Stroke Volume (SV) Response of
Normal (NL) & Failing Heart (HF) to Changes in Afterload

In addition to the hemodynamic derangements primarily due to the failing left
ventricle, a number of peripheral neurohumoral mechanisms become activated which,
although initially compensatory, over the long term accentuate the disease state while
indirectly worsening left ventricular function and pulmonary congestion (Table 2).
Initially, there is a marked increase in circulating catecholamines and sympathetic tone
resulting from stimulation of baroreceptors and chemoreceptors as the body attempts to
preserve cardiac output and blood pressure. Arteriolar vasoconstriction and increased
systemic vascular resistance result as well as venoconstriction, creating increases in
both left ventricular filling pressure and venous return. In addition, the increased heart
rate and contractility not only increase myocardial oxygen demand, but also, by
reducing diastolic relaxation time, reduce coronary blood flow to the myocardium and
further contribute to an imbalance between myocardial oxygen supply and demand.
Finally, prolonged sympathetic stimulation leads to a "down regulation" of beta-1

receptors residing within the failing myocardium, creating an intrinsic desensitization to
circulating catecholamines. In severely failing human hearts removed at the time of
cardiac transplantation, beta-adrenergic receptor density has indeed been observed to
be reduced by approximately 50% (17). Thus, the abnormal ventricle in congestive
failure not only is unable to provide a sufficient cardiac output under normal conditions,
but is also incapable of responding to inotropic stimulation during periods of increased
demand, further limiting the ability of the heart to meet the needs of the peripheral
circulation.

TABLE 2: Neurohormonal and Peripheral Changes in
Congestive Heart Failure
Neurohormonal Changes
a.
b.
c.
d.

Increased
Activation
Increased
Increased

plasma catecholamines
of renin-angiotensin-aldosterone system
arginine vasopressin (antidiuretic hormone)
atrial natriuretic factor

Peripheral Changes
a.
b.
c.
d.
e.

Increased systemic vascular resistance
Blunting of baroreceptor reflexes
Decreased vasodilatory response of peripheral vasculature
Altered regional flows
Venoconstriction

Adapted from Parmley, WW. Pathophysiology and Current Therapy of Congestive Heart Failure.
J Am Coll Cardiol 13: 774, 1989.

Reduction in effective renal blood flow, coupled with increased sympathetic
stimulation,

leads to

activation

of the

renin-angiotensin-aldosterone

system.

Angiotensin II has three effects which, over time, may become deleterious to CHF
patients. First, it is a potent vasoconstrictor that may contribute to excess systemic
vascular resistance. Second, it tends to facilitate sympathetic outflow that may
contribute to the already elevated levels of plasma catecholamines. Third, it feeds back
on the adrenal gland to release aldosterone and thus stimulates renal tubular sodium

reabsorption, increases salt and water retention, and contributes to the edema-forming
state seen in patients with heart failure.
Arginine-vasopressin (antidiuretic hormone) and atrial natriuretic factor have also
been found to be increased in patients with CHF (18,19) although it is not clear to what
extent these hormones contribute to the pathologic expression of CHF.

TABLE 3: Compensatory Mechanisms in Congestive Heart Failure
Autonomic nervous system
a. Heart
i. Increased heart rate
ii. Increased myocardial contractility
iii. Increased rate of relaxation
b. Peripheral circulation
i. Arterial vasoconstriction (increased afterload)
ii. Venous vasoconstriction (increased preload)

Kidney: renin-angiotensin-aldosterone
a. Arterial vasoconstriction (increased afterload)
b. Sodium and water retention (increased preload and afterload)
c. Increased myocardial contractility

Frank-Starling law of the heart
a. Increased end-diastolic fiber length (increased preload)
b. Increased end-diastolic volume (increased preload)
c. Increased end-diastolic pressure (increased preload)

Left ventricular hypertrophy
Peripheral oxygen supply
a. Redistribution of cardiac output
b. Altered oxygen-hemoglobin dissociation curve
c. Increased oxygen extraction by tissues

Anaerobic metabolism
Adapted from Hurst JW, et al. The Heart, 6th ediition. New York: McGraw-Hill Book Company (1986), p.323

These "compensatory" mechanisms operant in individuals with CHF (Table 3)
serve to increase both preload (ventricular end-diastolic volume and pressure) and
afterload (systemic vascular resistance and left ventricular wall tension). Although
initially helpful in increasing stroke volume by the Frank-Starling mechanism and
ensuring an adequate perfusion pressure to peripheral vascular beds, these peripheral
and neurohumoral changes eventually serve to raise myocardial workload and oxygen

demands. In cases of combined ischemic cardiomyopathy and heart failure, a vicious
cycle may result whereby cardiac energy utilization is increasingly taxed, causing an
imbalance between myocardial oxygen supply and demand. As a result the failing
heart loses additional contractile reserve and is less able to overcome increases in
filling pressures ana systemic vascular resistance. Further ventricular deterioration
ensues, yielding the clinical phenomenon of "congestive heart failure begetting further
congestive heart failure."
In addition to the degree of left ventricular dysfunction and functional impairment,
several clinical and laboratory abnormalities have been associated with reduced
survival among CHF patients (5). These include the degree of hemodynamic
derangement as expressed by cardiac index, left ventricular filling pressure and
systemic vascular resistance (9); the extent of exercise intolerance (10); the presence
of complex ventricular arrhythmias (5); decreased serum sodium levels below 120
mEq/L (20); and elevated serum norepinephrine levels (21). Most patients with CHF
who die do so as a result of either progressive hemodynamic deterioration or sudden
ventricular tachyarrhythmias (11).

5. OVERVIEW ON THE TREATMENT OF
CONGESTIVE HEART FAILURE

Major advances in the pharmacologic management of CHF have taken place in
recent years, largely as a result of increased understanding of pathophysiology,
improved precision in diagnosis, and increased awareness of the magnitude of the
morbidity and mortality rates associated with this syndrome. The prinicipal goals of
therapy for patients with congestive heart failure include:
1) improved performance of the left ventricle and prevention of further
myocardial dysfunction;
2) improved exercise tolerance and quality of life;
3) improved survival and reduced mortality secondary to progressive
hemodynamic deterioration and/or ventricular arrhythmias.

Traditional therapy consists of administering inotropic agents to enhance myocardial
contractility along with diuretic drugs to rid the body of the excess salt and water. In
addition, an increasing variety of vasodilating agents, including direct-acting
vasodilators, angiotensin-converting enzyme inhibitors, alpha-blockers, beta-blockers,
and, recently, calcium channel antagonists, has become available for the treatment of
heart failure.
Current medical therapy is aimed primarily at improving the derangements of the
peripheral circulation, which relieves symptoms while leaving the primary myocardial
insult unaffected. In cases of CHF due to ischemic cardiomyopathy, it may prove
rewarding to develop additional medical therapeutic strategies aimed at minimizing
any active ischemia contributing to the clinical state of congestive failure so as to
prevent, delay, or reverse myocardial failure and, perhaps, morbidity and mortality. The
following will be a discussion of available medical treatment options for CHF in the
outpatient setting.
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A. Inotropic Agents
Pharmacotherapy of CHF was first introduced in 1788, when Withering reported
clinical improvement in patients with "dropsy" after administration of foxglove (digitalis)
(22) . Over the following two centuries, inotropic therapy has remained the cornerstone
of therapy for heart failure. By inhibiting the Na+-K+ ATPase pump in myocardial cell
membranes, digitalis and related glycosides, including digoxin, indirectly increase
Na+-Ca++ exchange and, in so doing, increase intracytosolic calcium and contractility.
Although not all patients appear to benefit from therapy, digoxin has been observed to
exert favorable rest and exercise hemodynamic effects in many heart failure patients
(23) . Patients with strikingly dilated left ventricles and/or ventricular diastolic gallops on
exam represent those CHF patients having the most favorable response to the drug
(24) . Clinical experience suggests that in some patients the major benefit from digitalis
therapy may be secondary to a slowing of AV nodal conduction and ventricular
response in those CHF patients with concomitant atrial fibrillation rather than from a
positive inotropic effect per se.
Recently, conflicting data has sparked a reevaluation of the precise therapeutic
role of digitalis and digoxin. There have been reports suggesting that digoxin therapy
might aggravate rhythm disturbances and actually increase mortality among CHF
patients, especially those prone to ventricular ectopy and/or diuretic-induced
hypokalemia (25). Nevertheless, further studies comparing digitalis with various
therapeutic alternatives in CHF patients with normal sinus rhythm have reconfirmed
these agents' value in improving left ventricular function while preventing a worsening
of heart failure.

B. Diuretics
Diuretics, which became available for clinical use in the 1950s, represent the
second important advance in the medical therapy of CHF. The loop diuretics, including

furosemide, are generally the diuretic agents of choice with the administered dose
carefully adjusted so as to maintain extracellular fluid volume at an optimal state. These
agents act in the ascending limb of the loop of Henle, where approximately 25% of
normal sodium reabsorption in the nephron occurs. Loop diuretics decrease pulmonary
congestion and peripheral edema in CHF through venodilatation, reduction of left
ventricular end-diastolic pressure (preload), and reduction of extracellular fluid
overload. The efficacy of these drugs has been confirmed by numerous observations of
improved cardiac performance, reduced pulmonary capillary wedge pressure, and
resolved dyspnea and edema.
However, the possibility of volume depletion and electrolyte imbalance following
diuretic therapy also exists. Decreasing the preload may, in fact, reduce cardiac output
and aggravate the symptoms of fatigue which result from inadequate peripheral blood
flow. In addition, loop diuretic agents may cause excessive intravascular volume loss
as well as potassium depletion, both of which may lead to continued plasma renin,
arginine-vasopressin, and catecholamine secretion with secondary increases in
peripheral vasoconstriction and afterload (26).

C. Vasodilators
Appreciation of the important role played by peripheral vasoconstriction in the
pathophysiology of CHF has led to the development and widespread use of
vasodilators as an additional treatment modality. Vasodilators function by reducing
systemic vascular resistance via arteriolar and, in some instances, venous
vasodilatation, thereby decreasing ventricular workload while increasing cardiac
output. Symptoms attributable to a low flow state may be subsequently alleviated. In
addition to producing significant symptomatic benefits, recent clinical trials of various
vasodilator regimens have documented increased survival in some subgroups with
advanced heart failure already receiving digoxin and diuretics (27). By countering

rising systemic vascular resistances, vasodilator therapy tends to "unload" the failing
heart and improve myocardial function while, to some extent, interrupting the otherwise
downwardly spiraling course of left ventricular failure begetting more failure.
Of the available vasodilators, the angiotensin-converting enzyme inhibitors,
captopril and enalapril, appear to be the most effective. Acute administration of
captopril results in an increase in cardiac output, a decrease in ventricular filling
pressure, and an increase in renal blood flow (28). In double-blind, placebo-controlled,
long-term trials of both captopril (29) and enalapril (30), patients randomized to receive
angiotensin-converting enzyme inhibition improved both symptomatically and
functionally when compared to control. In addition, experimental studies suggest that
angiotensin-converting enzyme inhibitors may reduce the degree of ventricular
remodeling which occurs following acute myocardial infarction (31). Indeed, the recent
demonstration that the addition of enalapril to conventional therapy can significantly
prolong life in patients with severe heart failure has led to the general conclusion that
vasodilator drugs, and specifically the angiotensin-converting enzyme inhibitors,
should form part of any medical armamentarium used for patients with advanced CHF
unless there are contraindications such as hyperkalemia, renal insufficiency or renal
artery stenosis (32).

D. Combination Therapy
Any of the three therapeutic classes of drugs, inotropic agents, diuretics, or
vasodilators, can be used as first-line therapy for patients with CHF. Digoxin appears to
be most effective in patients who have more severe heart failure, dilated hearts, a
reduced ejection fraction, or CHF complicated by atrial fibrillation with a rapid
ventricular response. If the patient has evidence of volume overload, systemic or
pulmonary edema, it is likely that diuretics will be required. Angiotensin-converting
enzyme inhibitors are the only agents associated with both decreased mortality and
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improved clinical status, are speculated to slow the rate of hemodynamic deterioration,
and are generally the vasodilators of choice in patients with congestive heart failure.
In virtually all studies in which combination therapy with different classes of drugs
has been used, it appears that their hemodynamic effects are generally additive (Figure
3). This sets the stage for the gradual addition of agents as heart failure worsens with
maximal medical therapy including representative agents from all three classes.

FIGURE 3: Effects of Single and Combination Therapy on the
Frank-Starling Relationship in Congestive Heart Failure

Adapted from Parmley WW. Pathophysiology and Current Therapy of Congestive Heart Failure.
J Am Coll Cardiol 13: 781, 1989.

6. CALCIUM CHANNEL ANTAGONISTS IN THE TREATMENT OF
CONGESTIVE HEART FAILURE

Calcium channel antagonists have had a great impact on the practice of
cardiology. These agents have added significantly to the treatment of angina pectoris,
supraventricular arrhythmias, hypertension, Raynaud's and active peripheral vascular
disease, and hypertrophic cardiomyopathy complicated by diastolic dysfunction. Less
well described, however, is the imoact of calcium channel entry "blockers" in the
treatment of CHF in the setting of iscnemic heart disease. Indeed, in those cases which
active ischemia contributes to a state of myocardial dysfunction, agents which foster
relaxation of coronary arteries and increased coronary perfusion may potentially have
favorable effects. The calcium channel antagonists, particularly those of the
dihydropyridine class, are potent vasodilators as well as proven anti-ischemic agents,
reducing systemic vascular resistance and pulmonary capillary wedge pressure (due to
their afterload-reducing properties), as well as decreasing coronary vascular resistance
and improving the myocardial oxygen supply:demand ratio (33).
The calcium "channel" represents a pore in the sarcolemma selective for calcium
movement. The passage of calcium ions across this phospholipid membrane in both
myocardial and vascular smooth muscle cells is critical for muscle contraction. Once
inside the cardiac myoplasm, calcium is bound to troponin C, permitting actin-myosin
interaction to occur. In vascular smooth muscle cells, calcium ions bind with calmodulin
to form a complex which stimulates myosin light chain kinase to phosphorylate the
myosin light chains and allow actin-myosin interaction. In both cell types, these
respective chains of events promote muscle contraction.
Calcium channel antagonists "block" the entry of calcium through the calcium
channel in both myocardium and vascular smooth muscle, so that less calcium is
available to the contractile apparatus in both tissues. The result is both a negative

inotropic effect and vasodilation to greater or lesser degrees. In general, vascular
smooth muscle cells are more sensitive to the effects of calcium blocking agents than
are myocardial cells. Nevertheless, the use of calcium channel "blockers" in heart
failure has thusfar been discouraged by many authors because of the documented
potential of these drugs to exert negative inotropic effects, which may worsen left
ventricular dysfunction in certain individuals.
Although calcium antagonists are often considered a single class of drugs, it is
becoming increasingly clear that the chemical structures, receptor affinities, and
pharmacodynamic actions of these agents are diverse with varied spectra of clinical
activity. Indeed, a practical method of differentiating the various agents with respect to
their potential effects in heart failure is to contrast their relative pharmacodynamic
actions on coronary and peripheral vascular tone versus myocardial contractility (Table
4).

TABLE 4: Differential Effects of the Available
Calcium Channel Antagonists
Negative Inotropic Action (Reduced Contractility)
Peripheral Vasodilatation (Reduced Afterload)
Coronary Vasodilatation
Reflex Sympathetic Stimulation

N
+
++
+++
+++

Q.
+

+
++
+

V
++
+
++
+

N = Nifedipine (dihydropyridine class)
D = Diltiazem (benzothiazepine class)
V = Verapamil (phenylalkamine class)

As a general rule the dihydropyridine class, including nifedipine and felodipine,
represents the most potent vasodilating calcium channel antagonists while offering the
least relative negative inotropic effect. The inhibition of arterial smooth muscle occurs at
the level of arteriolar resistance vessels and large muscular arteries with only a modest
dilating effect upon venous capacitance vessels (34). In patients with moderate to
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severe congestive heart failure, acute administration of nifedipine produces a
substantial fall in systemic vascular resistance, resulting in a significant increase in
cardiac index and variable decreases in both left ventricular filling pressure and mean
arterial pressure without alterations in heart rate (35). In chronic studies, however, no
clear cut benefit has been documented. Additionally, CHF patients with "unpredictable”
decreases in cardiac output and precipitation of pulmonary edema following nifedipine
use have been reported, likely due to dose-dependent exaggerations in negative
inotropic action (36) and/or failures to decrease systemic vascular resistance (37).
In addition to the beneficial reduction in left ventricular afterload, dihydropyridine
calcium channel antagonists offer coronary vasodilatatory action potentially beneficial
to patients with concomitant congestive heart failure and myocardial ischemia. Such a
combination of direct anti-ischemic action (decrease in coronary vascular resistance
with subsequent increases in coronary blood flow and oxygen supply) with afterload
reduction (decreased peripheral vascular resistance and left ventricular wall tension)
may not only lead to a decrease, but in occasional settings perhaps a reversal, in
ventricular dysfunction. Following nifedipine therapy in CHF patients, myocardial
oxygen consumption

has been observed to diminish while the myocardial

arterio-venous oxygen difference is reduced, findings compatible with an improved
oxygen supply:demand ratio (38). Improved coronary perfusion with subsequent
improvement in the overall contractile state of a previously ischemic myocardium may
even serve to blunt the minimal negative inotropic properties of these agents and
prevent the precipitation of worsened left ventricular dysfunction and pulmonary edema
(36). Indeed, the second generation dihydropyridine compounds, including felodipine,
feature even greater vascular selectivity without clinically detectable inotropic effects,
stimulating renewed interest in these calcium channel antagonists as a treatment
option for patients with ischemic cardiomyopathy and congestive heart failure.
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7. FELODIPINE, A SECOND GENERATION DIHYDROPYRIDINE
CALCIUM CHANNEL ANTAGONIST

Felodipine is a second generation dihydropyridine calcium channel antagonist
and

a

structural

analogue

of

nifedipine.

Its

chemical

structure,

[4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,7-ethoxycarbonylpyridine] (Figure 4), was

originally synthesized with the aim of developing a new antihypertensive vasodilator
believed to interact with calmodulin so as to inhibit transmembrane ionized calcium
influx while selectively relaxing vascular smooth muscle. Clinical trials have since
documented its effectiveness not only as an antihypertensive agent but also in the
treatment of classic and variant angina pectoris, pulmonary hypertension, and
Raynaud’s phenomenon. Additionally, 15 open-label and double-blind international
studies of 200 CHF patients have provided some evidence for hemodynamic,
functional, and symptomatic improvement with felodipine in heart failure (Table 5).

FIGURE 4: Structural Formula of Felodipine

Cl
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Felodipine is believed to modulate the influx of ionic calcium across cell
membranes by interacting with calmodulin or other calcium-binding proteins found in
the cytoplasm of vascular smooth muscle cells. Following binding with calcium,
calmodulin is normally converted from an inactive to an active form able to influence
various cellular processes as a second messenger. Calmodulin normally binds a
maximum of 4 mol Ca++ per mol protein when assayed at high ionic strength. However,
in a concentration of 4 mol felodipine per mol of calmodulin, the binding is reduced to
approximately 2 mol Ca++ (39). This competitive binding of felodipine to calmodulin has
been confirmed by NMR analysis to occur allosterically with at least one of the other
calcium binding sites being altered as well. In fact, NMR analysis reveals that felodipine
binds to calmodulin with a binding constant of 10+5 - 10+6/mol, comparable to that of
ionized calcium (40). Hence, felodipine is believed to exert its vasodilatory effects by
inhibiting calcium uptake at the level of cytoplasmic calmodulin rather than by
"blocking" calcium channels directly.
All of the currently available calcium channel antagonists dilate vascular smooth
muscle while reducing myocardial contractility to various degrees. The relative potency
of a specific agent on smooth versus cardiac muscle fibers is referred to as its "vascular
selectivity." Initial in vitro studies showed that felodipine is greater than a hundred times
more potent in inhibiting contraction of rat portal vein preparations as compared with
paced rat papillary muscle residing in the same organ bath (41). Rat portal vein was
chosen because it exhibits physiologic properties similar to those of arterial resistance
vessels. Felodipine inhibited the vascular smooth muscle in concentrations roughly
beginning at 10'8mol/L without any significant negative inotropic myocardial effect,
which did not appear until the concentration was raised to IQ'5-4 mol/L, making for a
vascular:myocardiai potency ratio of 118:1. In fact, its vascular selectivity is
approximately eight times greater than that of nifedipine and sixteen times greater than
that of diltiazem when the vascular selectivity of verapamil is taken as the comparative
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standard (42). These pharmacologic properties of felodipine, highly vasoselective with
negligible negative inotropic properties, suggest that it might be useful as an
anti-ischemic agent in patients with ventricular dysfunction.
In addition to the in vitro evidence demonstrating a vascular selectivity
unsurpassed by other calcium channel antagonists, subsequent in vivo studies have
revealed

direct

coronary

vasodilatation

following

felodipine

administration.

Intracoronary injection of felodipine in open chest, anaesthetised pigs revealed that
felodipine caused a 50% reduction in coronary vascular resistance when given in
doses which did not affect regional cardiac wall motion (43). Subsequent clinical trials
with human subjects have demonstrated felodipine's favorable hemodynamic profile.
Felodipine was noted to produce dose-dependent reduction in coronary vascular
resistance and increases in coronary sinus blood flow and oxygen content while
significantly narrowing the myocardial arterio-venous oxygen difference in subjects
with angiographically proven coronary artery disease (44,45). In a subsequent
placebo-controlled, double-blind trial utilizing quantitative coronary angiography,
felodipine was noted to increase vessel diameter in the vicinity of coronary obstructive
lesions, producing significant dilatation of diseased coronary vessels both proximal
and distal to the areas of stenosis (46). In addition, sustained increases in stroke
volume and cardiac output without impairment of myocardial contractility were
observed following felodipine therapy in angina patients receiving concomitant
beta-blockade and fixed cardiac pacing to control against reflex sympathetic
stimulation (47). These findings suggest that felodipine may have much to offer in the
management of ischemic heart disease, creating reductions in coronary arterial
resistance without accompanying deleterious effects upon myocardial contractility.
Clinical studies evaluating the hemodynamic actions of felodipine among
patients with heart failure have revealed significant benefits, including decreases in
systemic vascular resistance and increases in stroke volume and cardiac output
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without apparent negative inotropic effects. In patients with severe heart failure,
felodipine was observed to cause an acute fall in mean arterial pressure from 91 to 68
mm Hg, a decrease in pulmonary capillary pressure from 22 to 14 mm Hg, and an
increase in cardiac index from 2.2 to 2.7 L7min/m2 (48). Repeated 5 mg oral doses of
felodipine in eleven "severe CHF subjects (ten of whom had angiographically proven
coronary artery disease) lead to significant dose dependent reduction in systemic
vascular resistance, a greater than 50% increase in cardiac index, a mean decline in
pulmonary capillary wedge pressure from 26 to 15 mm Hg (with a cumulative dose of
15 mg), and no significant change in overall left ventricular contractility. In addition, a
significant increase in coronary blood flow and decrease in myocardial oxygen
consumption were reported (49).
Recent trials utilizing double-blind, placebo-controlled designs in ambulant CHF
patients have, for the most part, confirmed the hemodynamic, clinical, and symptomatic
benefits with felodipine. When hemodynamic changes induced by felodipine were
considered along with treadmill exercise tolerance at baseline, following 2 days of
treatment, and at the conclusion of a four week treatment period, exercise duration was
found to increase significantly after two days of therapy with continuation of the
functional improvement throughout the remainder of the month. Of significance
hemodynamically, heart rate was unchanged, mean arterial blood pressure was
reduced, cardiac index was increased, and pulmonary capillary wedge pressure was
decreased both acutely and upon conclusion of four weeks of therapy (50).
Normalization of baroreflex control of vascular resistance has also been demonstrated,
an effect of potential therapeutic importance in the chronic management of patients with
heart failure (51). In a subsequent eight week, placebo-controlled, parallel group study
involving CHF patients maintained on stable doses of digitalis and diuretic, felodipine
(5-10 mg po BID) produced a 16% increase in cardiac output, 12% increase in stroke
volume index, and 21% decrease in systemic vascular resistance as compared to
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placebo. Additionally, treadmill exercise duration was significantly increased among
those patients receiving felodipine, and 91% of felodipine-treated patients noted
improvement in the level of dyspnea compared to 41% of patients in the control group
(52).
However, not all previous studies demonstrate such an abundance of beneficial
results. In a three week, placebo-controlled trial, CHF patients who received 5-10 mg
felodipine po BID exhibited a 16% increase in cardiac output, but without a significant
improvement in blood pressure, heart rate, pulmonary capillary wedge pressure,
exercise capacity, or symptoms when compared to control (53). Nonetheless, the
numerous beneficial hemodynamic and metabolic effects of felodipine, as reported in
the vast majority of clinical trials performed to date, suggest a potentially useful role for
felodipine in the joint management of CHF and ischemic heart disease.
In summary, felodipine is a second generation dihydropyridine calcium channel
antagonist which possesses potent peripheral and coronary vasodilatory effects
without causing significant myocardial inhibition or chronic reflexogenic tachycardia.
Among patients suffering from coronary heart disease, felodipine demonstrated
significant reductions in both peripheral and coronary arteriolar resistance with
secondary increases in stroke volume and cardiac output. In 14 of 15 previous clinical
trials involving 200 heart failure patients, felodipine (administered in doses ranging
from 0.1 mg/kg boluses to 60 mg po daily divided into either BID or TID regimens for up
to 6 months) has been observed to produce both acute and chronic improvements in
rest and exercise hemodynamics (Table 5). Improved clinical status and increased
exercise tolerance after 4 weeks and 8 weeks were also demonstrated during
double-blind, placebo-controlled studies. Indeed, the combination of anti-ischemic
action with a lack of myocardial inhibitory effect makes felodipine particularly attractive
for use in patients suffering from both coronary artery disease and left ventricular
dysfunction. However, no study performed to date has considered the efficacy of
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felodipine as adjuvent anti-ischemic therapy for coronary patients suffering from CHF
and already receiving maximal medical therapy, including an angiotensin converting
enzyme inhibitor (afterload reduction), a diuretic (preload reduction), and an inotropic
agent.

TABLE 5: Felodipine CHF Studies
Investiaator

Pyrsas§s-2t Sludy

Desian

Dose

Duration

N

Efesy

Emanuelsson

Hemodynamics

Open, acute

0.1 mg/kg

1 day

10

Rest &
exercise

(rest & exercise)

hemodynamics
improved
Tweddel

1) Hemodynamics
(rest & atrial

Open, acute

10 mg

1 day

14

paced);

improved;
Coronary flow

2) coronary venous
blood flow
Tweddel

Hemodynamics
(rest & exercise)

Rest & paced
hemodynamics

improved
Open

10, 20 mg

1 month

8

Rest &
exercise
hemodynamics
improved

Binetti

Hemodynamics

Single-blind,

5 mg TID

(rest & exercise)

placebo-control

10 mg TID
20 mg TID

4 days

13

Rest &
exercise
hemodynamics
improved

Timmis

Hemodynamics
(+ coronary)

Open, acute

5 mg TID

1 day

11

Hemodynamics,
+ coronary,
improved

Timmis

1) Hemodynamics
(rest & exercise)

Open, chronic

10 mg BID

4 weeks

10

2) Exercise duration

Rest &
exercise
hemodynamics
improved;
exercise
duration 24%
increased

Svedburg

1) Hemodynamics
(rest & exercise)
2) Exercise duration

Open, chronic

5-15 mg TID

4 weeks

9

Tan

1) Hemodynamics

Double-blind,
crossover vs
placebo

10 mg BID

3 weeks

15

Double-blind,
crossover vs

2.5 mg BID
or

placebo

10 mg BID

(rest & exercise)
2) Exercise duration

Jewitt

1) Hemodynamics
(low & high dose,
rest & exercise)
2) Exercise duration

Rest &
exercise
hemodynamics
improved
Rest &
exercise
cardiac index
increased;
hemodynamics
& exercise
duration not
improved

6 weeks

16

Hemodynamics
improved;
exercise
duration
14-41%
increased

TABLE 5: Felodipine CHF Studies (continued)
Dunselman

1) Hemodynamics
(rest & exercise)

Double-blind,
parallel vs

2) Exercise duration

placebo

10 mg BID

8 weeks

23

Hemodynamics
improved;
exercise
duration 27%
increased;
symptoms
reduced

Dunselman

Hemodynamics

Open

5-10 mg BID

6 months

10

Hemodynamics

Double-blind,

10 mg BID

3 weeks

18

(rest & tilt)

crossover vs

hemodynamics

placebo

improved

(rest & exercise)
Kassis

Amtorp

Binetti

Hemodynamics

Double-blind

(rest & tilt)

vs placebo

Acute regional

Acute

blood flow

10 mg BID

24 weeks

0.15 mg bolus, 1 day
.0075 mg/min
infusion

Hemodynamics
improved
Resting & tilt

21

8

Muscular &
hepatic blood
flow increased;
heart rate &
renal blood
flow unchanged

Muir

Hemodynamics

Open

0.1 mg/kg

1 dose

12

Hemodynamics
improved
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8. PURPOSE OF STUDY

Based upon an understanding of pathophysiologic principles and the initial
observations regarding felodipine therapy in CHF to date, the following hypotheses
were drawn:

1.

Acute and subacute ischemia may contribute significantly to the
chronic ventricular dysfunction seen in patients suffering from
ischemic cardiomyopathy;

2.

While as pure vasodilators calcium channel antagonists are probably
inferior to the angiotensin converting enzyme inhibitors in CHF, they
may play an important role in patients with ongoing active ischemia
by improving coronary perfusion;

3.

Felodipine, which offers vascular selectivity without negative
inotropic properties, may prove safe and effective in this setting.

Relatively few studies have addressed the long term clinical utility of the
dihydropyridine calcium channel antagonists in congestive heart failure. Rather, most
of the published data report hemodynamic effects, with attention primarily afforded to
afterload reduction properties. Indeed, no other center to date has considered the
potential

anti-ischemic

effects

of these

agents

in

CHF

patients

already

hemodynamically optimized with combination preload reduction (diuretic therapy) and
afterload reduction (angiotensin converting enzyme inhibition).
The purpose of this study, therefore, is to evaluate the clinical usefulness of
felodipine when added to enalapril, +/- furosemide, +/- digoxin in patients suffering from
congestive heart failure secondary to ischemic cardiomyopathy with the following
objectives:

1 . To ascertain the occurrence of active ischemia and its relationship
to rest and exercise left ventricular function in patients with
congestive heart failure secondary to coronary artery disease;
2. To evaluate the effects of felodipine as compared to placebo on
symptoms, signs, functional status, exercise tolerance, active
ischemia, and left ventricular function in this population;
3. To evaluate the safety and tolerability of felodipine versus placebo
in this population.
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9. MATERIALS AND METHODS

A. Location and Duration of Study
The study was conducted out of the Congestive Heart Failure clinic, West Haven
Veterans Affairs Medical Center, West Haven, CT. The study was completed between
January, 1989, and January, 1990.

B. Patient Population
Fourteen male patients averaging 69 years of age (range = 58-83), with New
York Heart Association (NYHA) class ll-lll CHF and antecedent coronary artery disease,
were prospectively studied. All subjects were on stable doses of enalapril (5-20
mg/day), +/- furosemide (0-120 mg/day), +/- digoxin (0-.250 mg/day) for at least six
weeks prior to study entry.
Patients were screened for heart failure by the classical signs and symptoms of
dyspnea on exertion, fatigue, orthopnea, paroxysmal nocturnal dyspnea, rales, jugular
venous distention, third heart sound or edema as well as meeting criteria for NYHA
functional class II or III (Table 6). Only those CHF subjects with baseline resting left
ventricular ejection fractions less than 45% and exercise tolerance times within a range
of 2-15 minutes by the modified Naughton treadmill protocol were considered.
TABLE 6: New York Heart Association Functional Classification (54)
Class l=No limitation. Ordinary physical activity does not cause undue fatigue, dyspnea,
palpitations, or angina.
Class ll=Slight limitation of physical activity. Such patients are comfortable at rest.
Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
Class lllsMarked limitation of physical activity. Although patients are comfortable at rest,
less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV=lnability to carry on any physical activity without discomfort. Symptoms of cardiac
insufficiency or angina are present even at rest.With any physical activity increased
discomfort is experienced.
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The history of coronary artery disease was established by either documentation
of a prior myocardial infarction with diagnostic Q waves on EKG and/or past enzyme
elevations, or a positive coronary angiogram demonstrating at least 70% obstruction in
at least one major coronary artery.
Subjects were all ambulatory at the time of study entry and capable of tolerating
withdrawal

of

any

concomitant

anti-ischemic therapy,

other than

sublingual

nitroglycerine as needed, without developing severe or unstable angina pectoris. They
were not functionally limited by either angina or claudication. In addition, all subjects
were free from potentially confounding medical conditions or concurrent medical
regimens as detailed in Table 7.

TABLE 7: Exclusion Criteria for Study Entry
1. Renal insuficiency with serum creatinine > 2.5 mg/dl or potassium > 5.5 meq/L;
2. Hepatic disease with elevated transaminases, bilirubin and/or alkaline phosphatase;
3.Severe pulmonary disease requiring chronic therapy with bronchodilators
(beta-agonists, anticholinergics, or theophylline) or steroids;
4.Unstable angina pectoris or angina limiting exercise tolerance;
5.Intermittent claudication limiting exercise;
6. Hypotension with systolic blood pressure less than 95 mm Hg;
7. Hypertension with blood pressure greater than 170/100 despite enalapril and
diuretic therapy;
8. Hemodynamically significant aortic or mitral valvular disease;
9. Acute myocardial infarction within three months preceding study entry;
10. Coronary bypass surgery or angioplasty within three months preceding study entry;
11 .Cerebrovascular accident within six months preceding study entry;
12. Documented history of cardiac arrest, ventricular fibrillation, or ventricular
tachycardia exceeding 30 seconds in duration;
13. Concurrent vasodilator therapy other than enalapril;
14. Concurrent cimetidine or anticonvulsant therapy.

C. Study Design
This

was

a

prospective,

ten-week,

double-blind,

randomized,

parallel,

placebo-controlled study. Following an initial two-week, single-blind placebo, baseline
period, subjects were randomized to receive either felodipine (2.5 mg po BID) or
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matching placebo for two weeks, after which time the dose was either doubled (5.0 mg
po BID) if blood pressure remained above 100/60 or else maintained (2.5 mg po BID)
throughout the remainder of the eight week, double-blind, treatment period (Figure 5).
Hence, the total study duration was approximately ten weeks.

FIGURE 5: Study Design
Digoxin*
Diuretic
Enalaprii
Placebo

Placebo

Felodipine ER
5.0 mg

2.5 mg

4

- -

Wks.

+

Baseline

2**

8

Double-blind Treatment

* Optional
**At end of Week +2, depending on BP, dosage may be titrated up to
5.0 mg felodipine ER b.i.d.

1. Baseline Period
All subjects entered into the study having been on maximal medical therapy as
prescribed by their regular internists or cardiologists (including various combinations of
enalapril, furosemide, and digoxin) for at least six weeks prior to entering into the two
week baseline period. At the initial visit a complete history was obtained and physical
examination performed. All concomitant anti-ischemic therapy, except sublingual
nitroglycerin, was withdrawn, and the subjects were started on placebo therapy at 2.5
mg po BID dosing (single-blind phase of study). During the second week of baseline,
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the following baseline tests were performed and data obtained:
1 .New York Heart Association questionnaire to determine NYHA functional class;
2. Dyspnea/fatigue questionnaire to determine severity of dyspnea/fatigue;
3. Minnesota Quality of Life symptomatic questionnaire to quantitate quality of life;
4.Serum chemistry panel for serum creatinine;
5. Rest and exercise Equilibrium Radionuclide Angiocardiography (ERNA) to
determine resting left ventricular ejection fraction and the change in LVEF at
peak exercise compared to rest;
6. 2-3 Exercise tolerance tests (modified Naughton protocol) to determine mean
exercise tolerance time;
7. Rest and exercise thallium-201 scintigraphy to determine extent of reversible
myocardial ischemia (% Total LV area ischemic) and ratio of reversible ischemia
to total myocardial perfusion defect area (% LV area at risk ischemic);
8. 48 hour Hotter EKG monitoring to determine the incidence of spontaneous
myocardial ischemia (both frequency and total duration of significant ST
segment depressions).
NYHA

functional

classification

and

dyspnea/fatigue

index

scores

were

determined by the investigator while the subjects completed the University of
Minnesota Quality of Life symptomatic questionnaire themselves. The NYHA functional
classification nonparametrically grades the severity of CHF by the level of activity at
which dyspnea occurs from 1 (least severe) to 4 (most severe) (Table 6). In contrast, the
dyspnea/fatigue index measures the impairment of customary activity by dyspnea
and/or fatigue and was scored from 0-4 with regards to functional impairment,
magnitude of task, and pace of task. These individual dyspnea/fatigue scores are later
added so as to obtain an index score, ranging from 0-12, providing another measure of
a patient's functional status. The University of Minnesota "Living with Heart Failure"
Quality of Life questionnaire allows the subjects to rate from 0-5 the extent to which
heart failure prevented them "from living as you wanted during the previous month"
among 22 possible situations. The individual Quality of Life scores for these different
situations were summed to obtain a total score, ranging from a possible 0 ("no"
limitations) to 110 ("very much" limited).
Equilibrium radionuclide angiocardiography (ERNA) studies, using a red blood
cell

labeling

technique

with

technetium-99m

pertechnetate

and

stannous
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pyrophosphate, allow for definition of the boundaries of the heart and calculation of
changes in chamber volume through the cardiac cycle, including left ventricular
ejection fraction (55). Resting left ventricular ejection fraction was calculated as the
mean of three 60 second acquisitions obtained with a high resolution parallel hole
collimator camera angled in a left anterior oblique (LAO) projection while the subjects
were in a supine position. Additional left ventricular ejection fraction determinations
were made at peak exercise with subjects pedaling an attached bicycle apparatus at
60-80 revolutions per minute. All images were recorded on Polaroid film for visual
interpretation by an experienced reader without knowledge of clinical history or other
test results.
Subjects performed symptom-limited maximal exercise treadmill tests using the
modified

Naughton

protocol

(Table

8).

Blood

pressure

and

a

12-lead

electrocardiogram were obtained every two minutes during exercise and every minute
during recovery. Heart rate was monitored continuously. Exercise tolerance time was
determined as a mean of two treadmill tests separated by at least 48 hours. If the two
maximal exercise times failed to be within 10% of each other, a third such test was
performed and averaged with the more similar previous exercise time.

TABLE 8: Modified Naughton Protocol (56)
Stage
i
2
3
4
5
6
7
8

Speed (mi/hr)
1.0
1.5
2.0
2.0
2.0
3.0
3.0
3.0

Grade (%)
0.0
0.0
3.5
7.0
10.5
7.5
10.5
12.5

Time (min)
2
2
2
2
2
2
2
2

02 Consumption (ml/kg/min)
9
10
12
16
18
22
26
30

One of the treadmill exercise tests was accompanied by stress-redistribution
thallium-201 scintigraphy of the heart. Stress thallium imaging allows for accurate
assessment of both the extent and duration of exercise-induced myocardial
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hypoperfusion, with both a sensitivity and specifity exceeding 90% (57). Areas of active
ischemia are able to be distinguished from areas of prior infarction depending on
whether "cold," unperfused areas laiar "fill in" or not, respectively, following a four hour
redistribution phase. Subjects began the exercise thallium study at least four hours
after eating a meal, and all nitrates were halted for at least 24 hours prior to the test.
Subjects were injected with 1.5 to 2 mCi of thallium-201 intravenously at peak exercise
and continued to exercise for 1-2 additional minutes. Scintigraphic imaging was begun
5 minutes after exercise (stress thallium study) and again 4 hours later (redistribution
thallium study). Ten minute images were obtained in the anterior, left anterior oblique
(45°), and left lateral (70°) projections. A scintillation camera equipped with 37
photomultiplier tubes, a high resolution parallel hole collimator and a V4 inch sodium
iodide crystal was used to record between 2,000-12,000 gamma emission counts. All
images were recorded on Poloroid film for visual interpretation by an experienced
reader without knowledge of clinical history or other test results.
Quantification of decreased/absent coronary perfusion was obtained by subtracting
the thallium-perfused ventricular area from a normal mean value previously calculated
from volunteers without coronary artery disease in each of the anterior, 45°, and 70°
imaging projections. These three respective scores were summed so as to determine
the total coronary perfusion defect, which was expressed as a percentage of the total
left ventricular area. Utilizing the results from both the stress and redistribution thallium
studies, the area of reversible myocardial ischemia (% total LV area ischemic) was then
calculated using the following formula:
% Total LV area ischemic = (% LV area unperfused in stress Tl) - ( % LV area unperfused in redistribution Tl).

In addition, a normalized ischemia index (% LV area at risk ischemic), relating the area
of reversible ischemia to total myocardial area at risk immediately following exercise
was calculated using the following formula:
% LV area at risk ischemic = (% LV ischemic)/(% LV area unperfused in stress Tl) X 100%.

Finally, a 48 hour Holter EKG recording was obtained for each subject at the
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conclusion of the baseline period, which was sent to Cardio Data Systems, Inc.
(Haddonfield, NJ) for computer-assisted detection of ST depressions of at least 0.1 mV
(80 msec after the J-point) exceeding one minute with episodes separated by at least
one minute.
The results of each of the above baseline studies were pooled and analyzed to
determine the comparibility between the treatment and control groups utilizing
unpaired t-test analysis with p values less than 0.05 taken as determinants of statistical
significance. Similiar analysis was performed for subgroups of subjects randomized to
either felodipine and placebo and demonstrating greater than 10% reversible
myocardial ischemia on baseline thallium-201 scintigraphy. In addition, correlational
analysis between baseline variables was performed utilizing either Pearson parametric
correlation analysis or the Spearmann nonparametric rank test with p values less than
0.05 taken as determinants of statistical significance.

2. Treatment Period
After completion of the baseline period, patients were randomized by arbitrary
allocation number to receive either felodipine 2.5 mg po BID or matching placebo at a
subject ratio of 1:1 (double-blind phase of study). All participants received the first dose
of the double-blinded study medication under close supervision in the CHF clinic at the
West Haven Veterans Affairs Medicial Center for four hours during which blood
pressure and heart rate were checked at hourly intervals.
Each subject was seen at two week intervals over the ensuing eight weeks with a
symptom review and physical examination performed at each visit. At the end of the
second week, subjects with blood pressures above 100/60 were titrated to 5.0 mg po
BID of either felodipine or placebo and continued at this dose for the remaining six
weeks of the treatment period, while those subjects with blood pressures at the end of
the second week below 100/60 were maintained on the 2.5 mg po BID dosage. The
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baseline enalapril, digoxin, and diuretic doses were kept unchanged throughout the
study period in all cases. At the conclusion of the eight-week treatment period, all
studies performed during the baseline period were repeated in the same order and
time of day.
The results of eight weeks of therapy on each of the symptomatic, functional, and
hemodynamic variables were pooled for the treatment and control groups. The mean
end of study values were compared against corresponding baseline values for each
variable within each respective subject group by paired t-test analysis. In addition,
mean differences between baseline and end of study variables were compared
between the treatment and control groups utilizing unpaired t-test analysis. All
statistical tests were based upon two-sided hypotheses at the 5% level of significance.

D. Informed Consent
In accordance with U.S. Food and Drug Administration regulations and Yale
University School of Medicine Human Investigations Committee guidelines, all subjects
were provided with both an oral and written description of the study protocol, including
potential attendant hazards. Written consent was obtained prior to entry.
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10. RESULTS

A. Baseline Clinical Data
Of the initial fourteen subjects, seven were randomized to receive felodipine and
seven were randomized to receive placebo. Refer to Table 9 for comparison baseline
clinical data between treatment and control groups. Table 10 lists significant
correlational relationships between different baseline variables pooled for the entire
cohort of subjects.
There were no statistically significant differences between treatment and control
groups with respect to the baseline clinical data (Table 9). There were, however, a few
aspects worth noting: mean New York Heart Association (NYHA) functional
classification and Minnesota Quality of Life symptom questionnaire scores were slightly
greater, and dyspnea/fatigue index scores were slightly less for the treatment group as
a whole, reflecting worse (though not statistically significant) baseline function and
symptomatology in the treatment group. In addition, the treatment group required a
daily mean furosemide dose of 46.7 mg as compared with only 24.0 mg among those
subjects destined to receive placebo, were only able to exercise for a mean 613.0
seconds as compared with 681.4 seconds for the control group, and had a mean
resting left ventricular ejection fraction of 25.3% as opposed to 34.9% among
individuals receiving placebo; all of which is suggestive that the active treatment group
had somewhat more severe symptoms and systolic dysfunction at baseline. However,
the control group displayed less ventricular reserve, with a 3.1% decrement in LVEF
from resting to peak exercise state as compared with a 2.0% rise among the treatment
group. Those subjects randomized to the treatment group received oral felodipine at a
total mean daily dose of 7.9 mg on a BID regimen.
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TABLE 9: Baseline Demographic Data
TREATMENT
GBQUElk-U*

CONTROL
GROUP (N=7)‘

SIGNIFICANT
DIFFERENCE

Age (years)
Body Weight (lbs)

68.1 +/- 8.2
180.4 +/-31.6

70.6 +/- 3.1
175.4 +/- 29.4

NS*“
NS

Enalapril dose (mg/day)
Digoxin dose (mg/day)
Furosemide dose (mg/day)

12.9 +/- 7.0
0.20 +/-0.07
46.7 +/- 37.2

12.1 +/- 12.5
0.19 +/- 0.07
24.0 +/- 8.9

NS
NS
NS

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.7+/- 0.5
7.1 +/- 1.3
30.9 +/-19.8
1.27 +/- 0.24

2.3 +/- 0.5
8.4 +/- 1.7
25.3 +/- 18.0
1.29 +/- 0.29

NS
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

136.9 +/-19.5
74.9 +/-10.9
74.6 +/- 10.9

124.9 +/- 7.6
68.9 +/- 10.7
68.9 +/- 13.2

NS
NS
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

25.3 +/- 6.2
2.0 +/- 7.3

34.9 +/- 7.7
-3.1 +/-7.1

NS
NS

Mean ETT (sec)

613.0 +/- 162.3

681.4 +/- 163.6

NS

# Subjects with (+) Thallium
% Total LV area ischemic (%)
% LV area at risk ischemic (%)

7
8.0+/- 7.1
37.3 +/- 25.3

7
8.0 +/- 6.9
46.0 +/- 20.0

NS
NS

#Subjects with (+) Holter
# ST Depressions/24 hours
min ST Depression/24 hours

1
1.4 +/-3.1
19.8 +/- 44.3

2
2.7 +/- 4.5
160.3+/- 325.2

NS
NS

BASELINE VARIABLE

‘Mean +/-1 standard deviation
“Statistical significance determined by unpaired t-test (2-tailed) with p<.05
“*NS = Not significant
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TABLE 10: Correlations Between Baseline Variables (N=14)
VARIABLE

VARIABLE

r*

Mean ETT (sec)
Mean ETT (sec)

NYHA Class
Dyspnea/Fatigue Index

.722

Dyspnea/Fatigue
Dyspnea/Fatigue

NYHA Class
Quality of Life Score

Rest LVEF (%)

Quality of Life Score

R*‘

SIGNIFICANCE*”

-.762

p<.02
p<.01

-.887
-.460

p<.01
p<.10

-.452

p<.10

* r = Pearson parametric correlation coefficient
**R = Spearman Rank nonparametric correlation coefficent as corrected forties
*** Significance= Two-tail probability of significant difference by chance alone with p< 05

TABLE 11: Baseline Reversible Myocardial Ischemia
By Thallium-201 Scintigraphy
TREATMENT GROUP (N=7)
% Total LV Area Ischemic*

Mean +/- S.D.

CONTROL GROUP (N=7)
% Total LV Area Ischemic*

18%
15
12
07
02
01
01

19%
16
09
04
03
03
02

8.0 % +/- 7.1

8.0 % +/- 6.9

*% Total LV Area Ischemic = estimated amount of left ventricular area demonstrating reversible perfusion
defects with stress and redistribution thallium-201 scintigraphy of the heart
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Correlation studies utilizing either Pearson parametric correlation analysis or the
Spearmann nonparametric Rank test were performed to identify any statistically
significant relationships between study variables prior to randomization (Table 10).
Inverse relationships were noted to exist between NYHA functional class (IV = worst
CHF) and both dyspnea/fatigue index score and mean exercise tolerance time (both of
which decrease as the CHF worsens). In addition, a direct relationship between
dyspnea/fatigue index scores and mean exercise tolerance times was observed.
Inverse relationships approaching significance were also observed between the
Minnesota Quality of Life questionnaire scores (which increase as CHF worsens) and
both resting left ventricular ejection fractions and dyspnea/fatigue index scores.
The extent of reversible myocardial ischemia, quantified as a percentage of total
left ventricular area, was nearly identical between the treatment and control groups
when analyzed as mean values. However, upon closer inspection there was
considerable variability within the each respective group (Table 11). Indeed, only three
out of seven individuals in the treatment group and two out of seven individuals in the
control group had baseline thallium studies revealing greater than 10% reversible
myocardial ischemia, a widely used criterion for reproducible reversible myocardial
ischemia at the Yale-New Haven Hospital and the West Haven Veterans Affairs
Medical Center nuclear medicine departments (from discussions with Frans Wackers,
M.D., and Robert Soufer, M.D.).
Subgroups of randomized patients with baseline reversible myocardial ischemia
by thallium-201 scintigraphy exceeding 10% were also examined. Table 12 features
the baseline clinical data of these treatment and control subgroups. As with the whole
treatment and control groups, the two respective subgroups were near identical except
that those in the treatment subgroup had greater mean furosemide requirements (70.0
mg/day vs. 20.0 mg/day), shorter mean exercise tolerance time (552.8 sec vs. 670.8
sec), and lower mean left ventricular ejection fraction at rest (23.7% vs. 37.5%), though
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only the latter difference was statistically significant. The treatment subgroup received
oral felodipine at a total mean daily dose of 8.3 mg on a BID regimen. There was no
statistically significant difference between the mean felodipine dose received by the
entire treatment group and that received by the treatment subgroup.

TABLE 12: Subgroup Baseline Demographic Data
TREATMENT

PLACEBO

BASELINE VARIABLE

GROUP <N=3)*

GROUP (N=2r

SIGNIFICANT
DIFFERENCE

Age (years)
Body Weight (lbs)

66.2 +/- 2.0
158.2 +/- 5.3

71.1 +/- 0.1
181.0 +/- 17.0

p<.05
NS“*

Enalapril dose (mg/day)
Digoxin dose (mg/day)
Furosemide dose (mg/day)

11.7+/-7.6
0.21 +/- 0.07
70.0 +/- 70.7

5.0 +/- 0.0
0.25 +/- 0.0
20.0 +/- 0.0

NS
NS
NS

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.7 +/- 0.6
7.3 +/- 1.5
23.7 +/- 13.5
1.27 +/- 0.31

2.5 +/- 0.7
8.5 +/- 3.5
24.0 +/- 1.4
1.20 +/- 0.14

NS
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

134.7 +/- 17.5
78.0 +/- 9.2
77.3 +/- 16.2

123.0+/- 7.1
71.0 +/- 4.2
76.0 +/- 17.0

NS
NS
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

23.7 +/- 4.5
4.3 +/- 5.8

37.5 +/- 3.5
-0.5 +/-2.1

p<.Q5
NS

Mean ETT (sec)

552.8 +/- 163.0

670.8 +/- 242.2

NS

# Subjects with (+) Thallium
% Total LV area ischemic (%)
% LV area at risk ischemic (%)

3
15.0 +/-3.0
52.3 +/-19.7

2
17.5 +/- 2.1
57.5 +/- 13.4

NS
NS

# Subjects with (+) Hotter
# ST Depressions/24 hours
min ST Depression/24 hours

0
0.0 +/- 0.0
0.0 +/- 0.0

1
11.0 +/- 0.0
813.0 +/- 0.0

-

‘Mean +/-1 standard deviation
“Statistical significance determined by unpaired t-test (2-tailed) with p<.05
***NS = Not significant
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B. Incidence of Reversible Myocardial Ischemia
Stress thallium-201 scintigraphy obtained at baseline revealed reversible
thallium defects and exercise-induced myocardial ischemia in all 14 subjects. 5/12
subjects had greater than 1 mm ST depressions in one or more precordial leads at
peak exercise. 7/12 subjects demonstrated no significant electrocardiographic changes
with exercise despite evidence of reversible ischemia by thallium scintigraphy. Two
subjects had left bundle branch blocks preventing accurate assessment of ST segment
changes. In none of the patients was the presence of ischemia accompanied by
angina. Although there was a trend towards greater ischemic area correlating with the
presence of positive EKG changes, there were no significant differences in either the
extent or location of reversible ischemia as detected by stress-redistribution TI-201
scintigraphy

between

those

subjects

with

and

without

corresponding

electrocardiographic evidence for exercise-induced ischemia (Tables 13,14).
48 hour Holter EKG monitoring with ST segment analysis confirmed spontaneous
myocardial ischemia in 3/5 of subjects demonstrating analagous changes on the
treadmill. No patients with electrocardiographically silent ischemia at time of stress
testing had significant ST segment depressions during Holter monitoring.

TABLE 13: Detection of Myocardial Ischemia with Exercise
Electrocardiography in Subjects with Reversible Perfusion Defects by
Stress-Redistribution TI-201 Scintigraphy
TI-201
RESULT

(+) EXERCISE
EKG (N=5)‘

(-) EXERCISE
EKG (N=7r

SIGNIFICANT
DIFFERENCE

% Total LV area ischemic (%)

9.4 +/- 7.8

5.4 +/- 6.1

NS“*

% LV area at risk ischemic (%)

46.3 +/- 21.6

34.5 +/- 23.2

NS

‘Mean +/-1 standard deviation
“Statistical significance determined by unpaired t-test (2-tailed) with p< 05
“*NS = Not significant
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TABLE 14: Distribution of Reversible Perfusion Defects by TI-201
Scintigraphy in Subjects with & without Exercise
Electrocardiographic Evidence for Myocardial Ischemia
AREA OF REVERSIBLE
ISCHEMIA ON TI-201
Anterior
Anterolateral
Anterobasal
Anteroseptal
Inferior
Inferolateral
Inferoseptal
Apiclal
Basoseptal
Posterolateral
Posteroseptal
Posterobasal

(+) EXERCISE
EKG(N=5)*
40%
20
20
00
20
60
40
40
40
60
20
20

(-) EXERCISE
EKG (N=7)“
29%
00
14
29
57
29
29
71
29
14
14
14

‘Percentage of subjects with (+) EKG signs of exercise-induced ischemia
“Percentage of subjects without (+) EKG signs of exercise-induced ischemia

C. Effects on Reversible Myocardial Ischemia
Effects of felodipine therapy on reversibly ischemic area were evaluated for the
treatment group and subgroup as well as compared against the control group and
subgroup respectively. Reversible myocardial perfusion defects noted on stress and
redistribution thallium-201 scintigraphy were not found to significantly decrease in the
treatment vs. control groups (Tables 15-17).

However, among the subgroups of

subjects with baseline thallium scans revealing greater than 10% reversible perfusion
defects, felodipine did significantly improve myocardial perfusion (Tables 18-20). The
mean % total LV area which was ischemic in the treatment subgroup decreased from a
mean of 15.0% +/- 3.0 at baseline to 5.3% +/- 3.5 following eight weeks of felodipine
treatment, approaching statistical significance (Figure 6). In addit.

i, the mean % LV

area at risk which was ischemic decreased significantly among the treatment subgroup
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from 52.3% +/- 19.7 at baseline to 23.3% +/- 26.1 at the conclusion of the study period
(Figure 7). This latter improvement also approaches statistical significance when
compared to reciprocal changes in the control subgroup.

D. Effects on Systemic Blood Pressure & Heart Rate
Eight weeks of felodipine therapy significantly reduced mean systolic pressure by
19.7 mm Hg (from 136.9 to 117.1 mm Hg) and reduced mean diastolic pressure by 5.4
mm Hg (from 74.9 to 69.4 mm Hg) in the treatment group (Tables 15-17). These
reductions represent significant changes over those noted in the control group. In
contrast, mean heart rate was not affected.
The treatment subgroup also demonstrated significant reductions in mean
systolic pressure (from 134.7 to 118.0 mm Hg) and mean diastolic pressure (from 78.0
to 70.0 mm Hg) without accompanying changes in mean heart rate (Table 18).

E. Effects on Rest & Peak Exercise LVEF
No deleterious effects upon systolic cardiac performance, as reflected in mean
left ventricular ejection fractions obtained at rest and at peak exercise, were noted
following eight weeks of felodipine therapy when compared either to baseline or to
subjects receiving placebo (Tables 15-17). In fact, mean resting LVEF increased from
27.3% to 30.1 in the treatment group and from 26.4% to 30.7 in the treatment subgroup
(though neither change was statistically significant). In the control group and subgroup
there were little changes in mean resting LVEF (from 35.6% to 34.1 and from 36.0% to
38.0, respectively).

F. Effects on Exercise Tolerance
Mean exercise tolerance time using the modified Naughton protocol for treadmill
exercise testing did not significantly increase among either the treatment or control
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groups (Tables 15-17). However, a trend towards greater functional improvement
following felodipine therapy in those subjects with baseline myocardial ischemia
exceeding 10% was demonstrated as the mean exercise tolerance time improved by
over half of a minute (36.2 sec) in the treatment subgroup while falling by over half a
minute (37.3 sec) in the control subgroup (Tables 18-20).

G. Effects on Symptomatic & Functional Status
No significant changes in either functional status (NYHA class), severity of limiting
symptoms (dyspnea/fatigue index), or quality of life (University of Minnesota
questionnaire) were found to occur among subjects receiving eight week felodipine
therapy as compared with baseline or to subjects receiving placebo (Tables 15-17).

H. Safety & Tolerability
Felodipine, administered at doses ranging between 2.5-5.0 mg po BID, caused
no untoward side effects among the seven individuals randomized to the treatment
group necessitating discontinuation of the drug and withdrawal from the study. One
subject in the treatment group (receiving 5.0 mg of felodipine po BID) was noted to
develop worsening pedal edema in weeks 6-8 of the study which was unassociated
with any other clinical symptoms or signs of worsening CHF.
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TABLE 15: Efficacy Data Comparing Treatment Group (N=7)
at Baseline & End of Study
SIGNIFICANT
VARIABLE

BASELINE VALUE*

8 WEEK VALUE*

DIFFERENCE’

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.7 +/- 0.5
7.1 +/- 1.3
30.9 +/- 19.8
1.27+/-0.24

2.7 +/- 0.5
7.4 +/- 1.9
27.9 +/- 21.5
1.36 +/- 0.17

NS***
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

136.9 +/- 19.5
74.9 +/- 10.9
74.6 +/- 10.9

117.1 +/- 16.3
69.4 +/- 9.6
78.9 +/- 8.6

p<.001
NS
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

27.3 +/- 6.4
2.0 +/- 7.3

30.1 +/- 9.0
0.3 +/- 5.5

NS
NS

Mean ETT (sec)

613.0 +/- 162.3

638.0 +/- 152.5

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

8.0+/- 7.1
37.3 +/- 25.3

5.0 +/- 4.6
22.1 +/- 28.3

NS
NS

* Mean +/-1 standard deviation
** Statistical significance determined by paired t-test (2-tailed) with p<.05
*** NS = Not significant
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TABLE 16: Efficacy Data Comparing Control Group (N=7)
at Baseline & End of Study
VARIABLE

BASELINE VALUE*

8 WEEK VALUE*

SIGNIFICANT
DIFFERENCE

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.3 +/- 0.5
8.4 +/- 1.7
25.3 +/- 18.0
1.29 +/-0.29

2.3 +/- 0.5
9.0 +/- 2.6
13.6 +/- 10.5
1.34 +/- 0.41

NS***
NS
p<.02
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

124.9 +/- 7.6
68.9 +/- 10.7
68.9 +/- 13.2

122.3 +/- 11.1
74.0 +/- 8.7
74.6 +/- 8.8

NS
NS
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

35.6 +/-8.1
-3.1 +/- 7.1

34.1 +/- 9.0
1.3+/-6.9

NS
p<.05

Mean ETT (sec)

681.4 +/- 163.6

688.0 +/- 137.9

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

8.0 +/- 6.9
46.0 +/- 20.0

5.0 +/- 4.9
27.0 +/- 24.4

NS
NS

* Mean +/-1 standard deviation
** Statistical significance determined by paired t-test (2-tailed) with p<.05
*** NS = Not significant

TABLE 17: Efficacy Data Comparing Treatment & Control Groups

DELTA VARIABLE*

TREATMENT
GROUP fN=7

CONTROL
GROUP (N=71“

SIGNIFICANT
DIFFERENCE

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

0.0 +/- 0.6
0.3 +/- 2.5
-3.0 +/- 13.4
0.09 +/- 0.11

0.0 +/- 0.0
0.6 +/- 1.9
-11.7 +/- 9.5
0.06 +/- 0.19

NS““
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

-19.7 +/- 8.3
-5.4 +/- 6.5
4.3 +/- 11.2

-2.6 +/- 7.5
5.1 +/- 11.2
5.7 +/- 7.3

p<.01
p<.05
NS

Rest LVEF (%)
Peak LVEF (%)

2.9 +/- 6.6
1.1 +/- 13.0

-1.4+/- 5.4
3.0 +/- 6.4

NS
NS

Mean ETT (sec)

25.0+/- 71.1

6.6 +/- 70.7

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

-3.0 +/- 9.0
-15.2 +/- 39.3

-3.0 +/- 5.1
-19.0 +/-30.0

NS
NS

* Delta = End of Study value- Baseline value
“Mean +/-1 standard deviation
“‘Statistical significance determined by unpaired t-test (2-tailed) with p<.05
““NS = Not significant
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TABLE 18: Efficacy Data Comparing Treatment Subgroup (N=3)
at Baseline & End of Study
VARIABLE

BASELINE VALUE*

8 WEEK VALUE*

SIGNIFICANT
DIFFERENCE

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.7 +/- 0.6
7.3 +/- 1.5
23.7 +/- 13.5
1.27 +/-0.31

2.7 +/- 0.6
8.3 +/- 2.5
20.0 +/- 14.8
1.33 +/- 0.25

NS***
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

134.7 +/- 17.5
78.0 +/- 9.2
77.3 +/- 16.2

118.0 +/- 20.8
70.0 +/- 10.0
74.7 +/- 9.2

p<.05
p<.05
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

26.4 +/- 4.0
4.3 +/- 5.8

30.7 +/- 11.5
0.0 +/- 6.6

NS
NS

Mean ETT (sec)

552.8 +/- 163.0

589.0 +/- 57.9

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

15.0 +/-3.0
52.3 +/- 19.7

5.3 +/- 3.5
23.3 +/- 26.1

p<.10
p<05

* Mean +/-1 standard deviation
** Statistical significance determined by paired t-test (2-tailed) with p<.05
*** NS = Not significant
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TABLE 19: Efficacy Data Comparing Control Subgroup (N=2)
at Baseline & End of Study
VARIABLE

BASELINE VALUE*

8 WEEK VALUE*

SIGNIFICANT
DIFFERENCE

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

2.5 +/- 0.7
8.5 +/- 3.5
24.0 +/- 1.4
1.20 +/- 0.14

2.5 +/- 0.7
8.0 +/- 4.2
17.5 +/- 7.8
1.25 +/- 0.35

NS***
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

123.0 +/- 7.1
71.0 +/- 4.2
76.0 +/- 17.0

123.0 +/- 15.6
76.0 +/- 14.1
75.0 +/- 12.7

NS
NS
NS

Rest LVEF (%)
Peak LVEF - Rest LVEF (%)

36.0 +/- 5.7
-0.5 +/- 2.1

38.0 +/- 2.8
3.5 +/- 2.1

NS
NS

Mean ETT (sec)

670.8 +/- 242.2

633.5 +/- 218.5

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

17.5 +/-2.1
57.5 +/-13.4

10.5 +/- 3.5
45.0 +/- 7.1

NS
NS

* Mean +/-1 standard deviation
** Statistical significance determined by paired t-test (2-tailed) with p< 05
*** NS = Not significant

TABLE 20: Efficacy Data Comparing Treatment & Control Subgroups

DELTA VARIABLE*

TREATMENT
GROUP (N=31“

CONTROL
GROUP (N=2r*

SIGNIFICANT
DIFFERENCE

NYHA Class
Dyspnea/Fatigue Index
Quality of Life Score
Serum creatinine (mg/dl)

0.0 +/- 1.0
1.0 +/- 3.6
-3.7 +/-20.8
0.07 +/-0.06

0.0 +/- 0.0
-0.5 +/- 0.7
-6.5 +/- 6.4
0.05 +/- 0.21

NS
NS
NS
NS

Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Heart Rate (beats/min)

-16.7 +/- 6.4
-8.0 +/- 2.0
-2.7 +/- 8.3

0.0 +/- 8.5
5.0 +/- 9.9
-1.0 +7-4.2

p<.10
P<.10
NS

Rest LVEF (%)
Peak LVEF (%)

4.7+/- 7.5
0.3 +/- 5.8

2.0 +/- 2.8
-1.0 +/- 2.8

NS
NS

Mean ETT (sec)

36.2 +/- 105.2

-37.3 +/- 23.7

NS

% Total LV area ischemic (%)
% LV area at risk ischemic (%)

-9.7 +/- 5.5
-29.0 +/- 9.5

-7.0 +/- 5.7
-12.5 +/- 6.2

NS
p<.10

* Delta = End of Study value- Baseline value
“Mean +/- 1 standard deviation
“‘Statistical significance determined by unpaired t-test (2-tailed) with p<.10
““NS = Not significant

% Total LV Area Ischemic (%)

FIGURE 6: % Total LV Area Ischemic
in Treatment and Control Subgroups
at Baseline & Following 8 Wk Therapy
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FIGURE 7: % LV Area at Risk Ischemic
in Treatment and Control Subgroups
at Baseline & Following 8 Wk Therapy
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11. DISCUSSION

Alterations in preload, afterload, and contractility provide the basis for the
available therapeutic interventions employed in the standard treatment of CHF. In CHF
the normal Frank-Starling ventricular reserve is depressed (Figure 1). Inotropic agents
shift the Frank-Starling preload-to-contractility relationship such that greater stroke
volumes occur with lower ventricular filling pressures. Diuretics decrease left
ventricular end-diastolic pressure and preload but do not improve cardiac output.
Afterload reduction with vasodilator therapy offers the possibility of increased cardiac
output while decreasing the cardiac workload. Yet, despite combination therapy with
these three classes of medical agents, the underlying heart disease remains
progressive in most patients, with only palliation of the peripheral manifestations of
heart failure and symptomatic improvement being achieved. Only vasodilator therapy
has been observed to correlate positively with improved survival rates.
This study has shown that pharmacologic intervention aimed at both afterload
modulation and relief of ischemia may have promise in the treatment of ischemic
cardiomyopathy and CHF. Felodipine is a dihydropyridine calcium channel antagonist
which reduces peripheral, coronary, and pulmonary vascular resistance. In addition,
felodipine is highly vasoselective, exerting minimal depressant effect on myocardial
contractility. Indeed, its afterload reducing properties and apparent lack of clinically
important negative inotropic effects have made it attractive for use as an anti-ischemic
agent in coronary patients with left ventricular dysfunction and congestive heart failure.
In previous hemodynamic studies of CHF patients on stable doses of digoxin and
diuretic, additional therapy with felodipine produced a persistent reduction in vascular
resistance and an increase in cardiac output, both at rest and during exercise. In
several reports, a decrease in pulmonary capillary wedge pressure during exercise has
also been observed. Yet, in other studies, correlations with increased exercise
tolerance and symptomatic improvement were not found, bringing into question the
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practical utility of this agent. In the present study, felodipine was investigated as
"add-on therapy" to patients with CHF secondary to coronary artery disease and
symptomatic despite standard maximal medical therapy including enalapril. In so
doing, it was postulated that any gains realized would be at least partially attributable to
improvement in coronary perfusion and reversal of active myocardial ischemia rather
than wholly to afterload reduction.

A. Prevalence of Clinically & Electrocardiographically Silent Ischemia
The finding of active myocardial ischemia by thallium-201 scintigraphy coupled
with an absence of exercise-limiting angina in all of the subjects, as well as a lack of
electrocardiographic evidence for ischemia in a majority of the subjects, were
unexpected observations from this study. These phenomena of "clinically silent" and
"electrocardiographically silent" myocardial ischemia have been previously reported in
coronary patients. However, the relative incidence of silent ischemia among patients
limited by symptoms of CHF has yet to be reported.
"Silent" or asymptomatic myocardial ischemia was first identified as a clinical
entity in the 1970's. Lindsey and Cohn reported that 26% of patients with coronary
artery disease, documented by cardiac catheterization, had ischemic EKG responses to
exercise testing without accompanying chest pain or anginal equivalents (58).
Subsequent estimates of silent ischemia among patients with a history of myocardial
infarction have ranged between 47-76% with similiar criteria of positive ST segment
depressions in the absence of anginal pain (59-62). In the present study, 5 out of 12
subjects without left bundle branch block (41.7%) demonstrated asymptomatic ST
segment depressions with exercise. Ambulatory EKG monitoring with ST segment
analysis was also undertaken in an attempt to obtain an objective measure of transient
ischemia during daily life. Three of the 5 subjects with exercise-induced ST
depressions also had spontaneous ST segment changes recorded on ambulatory EKG
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monitoring while no subjects with baseline exercise tests lacking EKG changes
demonstrated evidence for ischemic episodes on ambulatory EKG analysis. ST
segment depressions have also been difficult to reproduce in previous experimental
studies, having been recorded intermittently from the edge of ischemic segments, on
patches of pericardium during endocardial ischemia, and from the ventricular wall
opposite an ischemic segment (63-65). Thus, electrocardiographic evidence for ST
segment depression may represent an insensitive marker of transient ischemia.
In the remaining 7 of 12 subjects without left bundle branch blocks (58.3%), there
was no electrocardiographic evidence for myocardial ischemia by either exercise EKG
or ambulatory EKG monitoring despite scintigraphic evidence for reversible coronary
perfusion defects. In the only other studies utilizing thallium-201 perfusion defects and
the absence of angina as critieria for silent ischemia, Assey et al. reported a similiar
incidence of negative EKG responses to exercise (59%), while Gibson found that 55%
of patients and Hecht et al. reported 68% of patients with electrocardiographically silent
ischemia (66-68). These findings confirm the relative insensitivity of 12-lead EKG
monitoring as compared to thallium scintigraphy for detection of myocardial ischemia
(69-71). A possible explanation for electrocardiographically silent ischemia may
involve the magnitude of inducible ischemia: conceptually, a threshold of ischemic area
may be necessary to produce electrocardiographic change. Anatomic localization of
exercise-induced ischemia is another potential explanation for electrocardiographically
silent ischemia (72). Neither relation was confirmed by the present study (Tables
13,14).
Unfortunately, there is no widely available "gold standard" to validate the
accuracy of noninvasive tests in delineating myocardial ischemia. However, most
published reports on silent myocardial ischemia have used the presence or absence of
ST depression to define ischemia while excluding from consideration those patients
without ST depression. The present study demonstrates that the amount and
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distribution of reversibly ischemic myocardium may in fact be similiar in patients with
and without exercise-induced ST depression. Consequently, studies that have relied
solely on electrocardiographic criteria have probably greatly underestimated the
number of patients with silent ischemia. Results from the present study highlight the
inaccuracy that may follow conventional EKG stress testing not accompanied by angina
and/or ST segment depression.

B.Reduction of Reversible Myocardial Ischemia
Reversible areas of coronary hypoperfusion detected by thallium scintigraphy
may reflect the overall magnitude of myocardial area at risk for future infarction and,
hence, the

potential

for worsened

pump failure and

possible creation

of

arrhythmogenic foci. Previous in vitro and in vivo studies have revealed direct coronary
vasodilation following felodipine administration (46), while hemodynamic studies have
confirmed the coronary vasodilatory properties of felodipine in man (47-49).
Whether or not maximal medical therapy with enalapril, furosemide, and/or
digoxin alters the balance between myocardial oxygen supply and demand in such a
collection of patients was not addressed by this study. Rather, the addition of felodipine
(5.0-10.0 mg/day) to such a medical regimen was observed to significantly reduce the
amount of reversible ischemia as detected by thallium scintigraphy in the treatment
subgroup (including patients with baseline reversible defects exceeding 10%). A
normalized ischemia index was calculated for each subject as the % LV area at risk
which was ischemic. This index may represent a more physiologic gauge for potential
therapy than % total LV area which was ischemic, as it reflects the extent to which
diseased myocardium represents salvagable versus irreversibly scarred, infarcted
tissue. Indeed, significant decreases in the normalized ischemia index were observed
following felodipine administration in the treatment subgroup as compared with
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baseline (Table 18, Figure 7). This decrease was also found to approach statistical
significance when compared to the control subgroup (Table 20).
Whether or not felodipine is equally effective for patients with smaller initial
defects remains unknown given the statistical constraints of the study. More subjects
will be needed before any firm conclusions may be drawn regarding the effects of
felodipine upon reversible ischemia in all patients with concomitant ischemic
cardiomyopathy and CHF. Indeed, this preliminary study is intended to assist in the
identification of new inclusion criteria and promising clinical markers for future
investigation.

C. Absence of Deleterious Effects upon Ventricular Function
Felodipine administration was not accompanied by a further decline in left
ventricular function. Rather, mean resting left ventricular ejection fraction appear to
have improved in the treatment group as compared to the control group. In addition,
there exists an important trend to be noted: the subgroup of subjects with baseline
perfusion defects exceeding 10% had the largest improvement in mean left ventricular
ejection fraction following felodipine therapy. Perhaps the relative gains made in left
ventricular ejection fraction indirectly reflect the significant reduction in reversible
ischemia (see section B) and/or systolic and diastolic blood pressures (see section D)
observed in this subgroup and result from similiar improvements in the myocardial
oxygen supply:demand ratio and contractility.

D. Afterload Reduction
In addition to acting as a coronary vasodilator, felodipine lowers systemic
vascular resistance and clinically may serve as a potent afterload reducer. In the
present study both systolic and diastolic blood pressure were noted to fall significantly
following chronic felodipine therapy as compared with placebo (Table 17). In contrast,
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the control group showed no significant hemodynamic changes. Though not directly
measured in this study, these changes may contribute to an improvement in the
myocardial oxygen supply:demand ratio via afterload reduction (decreasing systemic
vascular resistance) in addition to that attributable to direct anti-ischemic action
(decreasing coronary artery vascular resistance).

E. Improvement in Exercise Tolerance
Maximal exercise tolerance, measured with the modified Naughton treadmill
protocol and quantified as total exercise duration, has proved to be a useful index of
functional status in patients with CHF (73). An increase of exercise capacity has indeed
become an essential requirement for proof of drug efficacy in many clinical trials; this
despite the questionable suitability of such "maximum" stress tests to patients with heart
failure. The justification for such a test is the a priori belief that patients can achieve a
maximal oxygen consumption which is an indicator of their overall physical capacity
limited by the cardiovascular system (74). Examination of the baseline data indeed
confirmed an inverse correlation between the maximum exercise stage completed and
NYHA functional class.
Dyspnea and fatigue were the symptoms which limited physical activity in the
subjects studied. The precise cause of these symptoms remains uncertain (75,76).
Because of the limited cardiac output state in ischemia-related CHF, rising pulmonary
vascular pressures and redistribution of peripheral blood flow away from skeletal
muscle would be expected to occur with increasing exercise. By primarily acting on
arteriolar smooth muscle, the dihydropyridine calcium channel antagonists are known
to counteract the compensatory vasoconstrictive reflex following congestive cardiac
failure and, in so doing, limit secondary rises in oxygen extraction, anaerobic
metabolism, accumulation of lactic acid, and local symptoms, while increasing duration
of exercise to exhaustion (50). However, in patients already being treated with

58
angiotensin-converting enzyme inhibition (enalapril 5-20 mg/day), further improvement
in regional hemodynamic changes may not be possible, resulting in suboptimal
delivery of blood to exercising muscle and reappearance of symptoms. In the present
study, such an addition of felodipine to combination medical therapy failed to
significantly increase mean exercise tolerance time on the treadmill. However, the 36
second gain (or, roughly, quarter of a stage in the modified Naughton protocol) made
by the treatment subgroup versus the 37 second decline seen in the control subgroup
following eight weeks of therapy (Table 20) represents a promising trend which needs
to be followed up with additional subjects in order to achieve statistical significance.

F. Unchanged Functional & Symptomatic Status
One of the goals of therapy in patients with chronic heart failure is improvement in
symptoms, stabilization or improvement in functional abilities, and improved comfort for
the remaining duration of life. During the past decade, there has been increasing
documentation of the scientific validity of global quality of life measures which quantify
and reliably describe a variety of subjective features of health status (77). In the present
study three such tests were utilized: the NYHA functional classification, the
dyspnea/fatigue index, and the University of Minnesota Quality of Life symptom
questionnaire.
Poor correlation has repeatedly been demonstrated between measures of
ventricular performance (including ejection fraction) and quality of life attributes, a
phenomenom confirmed in this study (78). Rather, symptomatic improvement is
generally believed to be

primarily determined by alterations in

peripheral

hemodynamics and blood distribution (79). In the present study, the addition of
felodipine to a daily medical regimen including enalapril yielded no significant
amelioration of symptoms or improvement in functional abilities from those present at
baseline. Perhaps a relative localization of pharmacologic action to the coronary
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vascular bed provides an explanation for why felodipine therapy did not improve either
functional or symptomatic status over placebo in this group of CHF patients already on
stable doses of a peripheral vasodilator.

G. Tolerance & Side Effect Profile
Felodipine was well tolerated by those subjects randomized to receive the active
drug in a daily dose range of 5.0-10.0 mg. Only one individual reported worsening
pedal edema unassociated with other signs of worsening heart failure, a common
though not yet well understood side effect of the dihydropyridine calcium channel
antagonists. No subjects complained of palpitations, lightheadedness, increased
dyspnea, or anginal discomfort; nor were any subjects found to suffer from reflex
tachycardia, profound hypotension, new ischemic changes on electrocardiogram, or
worsened rales on serial physical examinations. As opposed to previous studies with
other calcium entry blockers, there were no significant rises in serum creatinine levels
or declines in either left ventricular ejection fractions or exercise tolerance time. Indeed,
if anything all subjects receiving felodipine were partially relieved from their heart
failure symptoms and improved clinically.
No subjects receiving placebo suffered an adverse effect from medication.
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12. CONCLUSIONS

Based upon careful review of the data, the following conclusions may be drawn:

1. Subacute, reversible myocardial ischemia is seen in high prevalence among
patients with a history of coronary artery disease and limited by CHF;
2. Both clinically and electrocardiographically silent myocardial ischemia was
demonstrated in 58% of subjects having scintigraphic evidence for reversible
myocardial ischemia;
3. Felodipine's anti-ischemic properties allow for significant reduction in the
normalized area of active myocardial ischemia in subjects with initial thallium
scans revealing greater than 10% reversible perfusion defects;
4. Significant reductions in both mean systolic blood presure and diastolic blood
pressure were observed among subjects receiving eight weeks of felodipine
therapy versus placebo;
5. Felodipine, which offers vascular selectivity without
properties, can

negative Inotropic

be safely administered to CHF patients with

ischemic

cardiomyopathy in a dose range of 5.0-10.0 mg/day divided into a BID
regimen;
6. No clear cut clinical benefit in terms of either exercise tolerance, functional
status, or quality of life assessment was demonstrated by the addition of
felodipine to this group of CHF patients;
7. Future studies documenting the clinical efficacy of felodipine in coronary
patients limited by symptoms of CHF and having scintigraphic evidence of
greater than 10% reversible myocardial ischemia are warranted.
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